secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001828185-24-000089
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus/Arbutus HBV data: 23% HBsAg loss with nivolumab; 2 functional cures in Phase 2b
--------------------------------------------------------------------------------

- IM-PROVE II Group C: 23% (3/13) on imdusiran + VTP-300 + low-dose nivolumab achieved HBsAg loss by Week 48.
- HBV003: 8 participants achieved HBsAg loss; 2 met functional cure criteria; 2 seroconverted to HBsAb.
- In HBV003, 66% (6/9) who discontinued NUCs remained off therapy >6 months, 2 meeting functional cure.
- Both regimens were generally well tolerated with no treatment-related SAEs reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000089/0001828185-24-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000089/brns-20241115.htm
  HTML page:      https://secwatch.observer/filing/0001828185-24-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer